Hikal Gears Up for Q3 Reveal on 11th February; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Hikal Q3 results FY26 are scheduled to be announced on 11th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Hikal Q3 Results 2026 Preview

• Hikal’s revenue is expected to be in the range of ₹447.70 crore, a 1.15% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall 6.01% YoY. 
• Net profit is ₹17.20 crore, fall 6.01% YoY 
• EBITDA to fall 9.95%

Hikal Share Performance 

• Over the past six months, Hikal’s share price has risen by 15.09% to ₹575.15.
• Moreover, over the past year, the stock has increased by 14.83%.
• Despite this weak short-term performance, Hikal’s stock has delivered a financially sound 217.06% return over the past 5 years.
• As of 10th February 2026, the stock traded at ₹575.15 per share.

Key Factors to Watch for Hikal  Q3 Results FY26

• Revenue & Segment Performance: Trends in pharmaceutical (API & CDMO) and crop protection sales, especially given recent headwinds and deferments affecting volumes.
• Profitability & Margins: EBITDA and net profit margins, including the impact of fixed cost absorption, pricing pressure, and raw material cost volatility.
• Regulatory & Customer Offtake Recovery: Progress on regulatory remediation (e.g., FDA issues) and restoration of customer shipments, which influences future revenue momentum.
• CDMO Pipeline & New Product Ramp‑up: Advancement of high‑value CDMO projects and commercialization of new molecules, a key future growth driver.
• Cost Control & Operational Efficiency: Management of operating expenses, capacity utilization and any improvement initiatives to boost cash flows and margins.

Final Thoughts

Hikal will announce its Q3 FY26 results on 11th February 2026. Analysts expect 0.30% revenue growth, a 6.01% fall in PAT, and a 9.95% fall in EBITDA. Hikal focuses recovery in API/CDMO and crop protection sales, margin improvement, new product ramp-up, operational efficiency, and regulatory resolution.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Alfred Herbert India Ltd Q3 Results FY26 Preview: PAT falls 3%

Salora International Q3 Results FY26 Preview: PAT falls 18.54%

Kuantum Papers Q3 Results FY26 Preview: PAT falls 29.85%

AK Capital Services Ltd Q3 Results FY26 Preview: PAT falls 16.86%

Glance Finance Q3 Results FY26 Preview: PAT rises 58.48%